Tag: 600-700

Prioritizing pharmaceuticals based on environmental risks in the aquatic environment in China was written by Guo, Jiahua;Liu, Shan;Zhou, Li;Cheng, Bo;Li, Qi. And the article was included in Journal of Environmental Management in 2021.Reference of 145040-37-5 This article mentions the following:

In last two decades, the number of detected activated pharmaceutical ingredients (APIs) in the natural environment worldwide has increased due to their widespread use in daily life. However, given the large number of APIs that are currently in use (approx. 850 are on the market in China), it is impractical to investigate the occurrence, ecotoxicol. effects, and perform environmental risk assessment for all drugs. Therefore, it is crucial to rank and prioritize APIs in the environment to identify the compounds of high concern. In China, since information on API usage is not available, an attempt was made to use the number of products per API (the number of pharmaceutical commodities that contain a particular API) on the market multiplied by its daily dose (average daily dose of medication for adults used for the primary therapeutic purpose) to replace the usage in the exposure modeling. Coupled with the hazard assessment, including acute and chronic toxicity of aquatic ecol. effects and potential effects related to the therapeutic mode of action, risk scores were estimated and used for ranking. Application of the approach was illustrated for 259 APIs with product number no less than 4. A list of 20 APIs was finally identified as a potential priority, including drugs of cardiovascular, nervous system, respiratory system, musculoskeletal system and antibiotics. In the future, this approach could be applied to prioritize APIs in other countries/regions where information on API usage are limited or non-existent. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Reference of 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

The Zuellig Pharma Korea Consortium Database: an on-site drug wholesales database for pharmacoepidemiological studies using real-world data was written by Jeong, Han Eol;Oh, In-Sun;Li, Junqing;Vilfeu, Erwan;Ryuu, Sang A.;Shin, Ju-Young. And the article was included in International Journal of Clinical Pharmacology and Therapeutics in 2019.Category: imidazoles-derivatives This article mentions the following:

Objective: To assess the value and representativeness of the Zuellig Pharma Korea Consortium (ZPK-C) database, which contains drug wholesales data collected in a weekly interval, for its prospective use as a data source for pharmacoepidemiol. studies. Materials and methods: Wholesales and nationwide claims data of antidiabetic and antihypertensive products were compared in 17 administrative regions using the defined daily dose per 100,000 inhabitants per day (DID) and its proportion for standardized evaluation. Results: We found regional concordance in 12 and 13 regions (out of 17) for antidiabetic and antihypertensive products, resp., of which concordance was higher in rural than metropolitan regions. Conclusion: The ZPK-C showed potential as a valuable data source for pharmacoepidemiol. research. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Category: imidazoles-derivatives).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Synthesis of the anti-hypertensive drug olmesartan medoxomil in greener approach was written by Shanker, Ch. Gouri;Sujitha, D.;Kumar, D. Aravind;Sudhakar, K.. And the article was included in Heterocyclic Letters in 2018.Reference of 145040-37-5 This article mentions the following:

Proton and metal ion-exchanged Montmorillonite and Copper-Aluminum Hydroxyapatite (Cu-HAP) catalysts were effectively used in the esterifiaction, C-N bond formation and Detritylation in methanol efford Olmesartan Medoxomil in good yields. The catalysts were quant. recovered from reaction mixture by simple filtration and reused for four cycles with consistent activity. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Reference of 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Design and evaluation of Candesartan cilexetil solid dispersion incorporated in hard gelatin capsule was written by Shree, A. J. Divya;Ravichandra, V. D.. And the article was included in International Journal of Pharmaceutical Sciences and Research in 2022.Computed Properties of C33H34N6O6 This article mentions the following:

Candesartan cilexetil is widely used for the treatment of hypertension. Candesartan cilexetil is a pro-drug administered orally, rapidly converted to its active metabolite candesartan during absorption in the gastrointestinal tract. Candesartan cilexetil is a BCS II drug that is practically insoluble in the water of 0.00771 mg/mL & it has a low dissolution rate, hence; to improve dissolution rate & bioavailability, solid dispersion of Candesartan cilexetil were prepared by kneading method, solvent evaporation method & Microwave method in 1:0.5, 1:1 & 1:1.5 ratios of Candesartan cilexetil and hydroxy Pr beta-cyclodextrin/PVP K 30. Further, the SDs were filled into empty hard gelatin capsules with excipients like starch (8%), lactose, talc & Aerosil by manual capsule filling method. The formulated solid dispersions were evaluated for drug content and in-vitro dissolution studies. Accelerated stability studies was conducted for the optimized SD formulations, the optimized drug & carrier SD were confirmed & characterized by FT-IR. The drug content of the prepared Candesartan cilexetil SD formulations was found to be range from 94.35 ± 0.95% to 98.44 ± 0.56%. XRD studies showed that the drug exists in an amorphous state as there was no drug peak in the formulation. The solid dispersion of Candesartan cilexetil prepared by kneading method with HPβCD (1:1.5) showed a maximum drug release of 94.05 ± 0.11% compared to other solid dispersion formulations. It is concluded that the dissolution rate of Candesartan cilexetil can be improved by the solid dispersion method. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Computed Properties of C33H34N6O6).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Computed Properties of C33H34N6O6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Advancing the Therapeutic Efficacy of Bioactive Molecules by Delivery Vehicle Platforms was written by Tsiailanis, Antonis D.;Tzakos, Andreas G.;Mavromoustakos, Thomas. And the article was included in Current Medicinal Chemistry in 2021.Recommanded Product: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate This article mentions the following:

Drugs have to overcome numerous barriers to reach their desired therapeutic targets. In several cases, drugs, especially the highly lipophilic mols., suffer from low solubility and bioavailability and therefore their desired targeting is hampered. In addition, undesired metabolic products might be produced or off-targets could be recognized. Along these lines, nanopharmacol. has provided new technol. platforms, to overcome these boundaries. Specifically, numerous vehicle platforms such as cyclodextrins and calixarenes have been widely utilized to host lipophilic drugs such as antagonists of the angiotensin II AT1 receptor (AT₁R), as well as quercetin and silibinin. The encapsulation of these drugs in supramols. or other systems refines their solubility and metabolic stability, increases their selectivity and therefore decreases their ED and improves their therapeutic index. In this mini review we report on the formulations of silibinin and AT₁R antagonist candesartan in a 2-HP-β-cyclodextrin host mol., which displayed enhanced cytotoxicity and increased silibinin′s and candesartan′s stability, resp. Moreover, we describe the encapsulation of quercetin in gold nanoparticles bearing a calixarene supramol. host. Also, the encapsulation of temozolomide in a calixarene nanocapsule has been described. Finally, we report on the activity enhancement that has been achieved upon using these formulations as well as the anal. and computational methods we used to characterize these formulations and explore the mol. interactions between the host and quest mols. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Recommanded Product: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Recommanded Product: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects was written by Yerino, Gustavo A.;Feleder, Ethel C.;Halabe, Emilia K.;Diaz, Liliana;Sakson, Mario;Iglesias, Mariana;Haddad, Tobias;Roldan, Emilio;Mondelo, Nelida. And the article was included in International Journal of Clinical Pharmacology and Therapeutics in 2022.Safety of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate This article mentions the following:

A fixed-dose combination (FDC) of candesartan cilexetil, hydrochlorothiazide and rosuvastatin (CC/ HCTZ/RSV) has been developed to enhance patient compliance in the primary prevention of cardiovascular diseases. To evaluate if the combination of the product components in the new FDC capsule formulation affects their resp. pharmacokinetic and in vitro dissolution patterns. Materials and methods: In vitro dissolution profiles were compared in USP-43 and in biorelevant dissolution media. In vivo comparisons were obtained in a randomized, open-label, single-dose, two-treatment, two-way crossover study in 24 healthy subjects. During each treatment period, subjects received the test formulation (FDC hard capsule containing CC/HCTZ/RSV) or the reference formulation (co-administration of a FDC CC/HCTZ tablet and a RSV tablet). Plasma samples were collected periodically over 48 h post-dose. Safety and tolerability were assessed. Dissolution profiles of all active drugs in the Test (capsule) and Reference Products (as tablets) were within the tolerance dissolution criteria of USP-43 conditions. HCTZ dissolution profiles were closely similar whereas those for RSV and CC did not match at specific pHs. In the pharmacokinetic study, the 90% confidence intervals (CIs) for the geometric least-square mean ratios of Cmax, AUC0-last, and AUC0-inf were 0.95 – 1.18, 0.95 – 1.15 and 0.95 – 1.13 (CC); 0.91 – 1.10, 0.96 – 1.08, and 0.96 – 1.09 (HCTZ) and 0.82 – 1.23, 0.81 – 1.13, and 0.82 – 1.12 (RSV), resp. All adverse events were mild. The new FDC product (Sinlip Prevent), a stable FDC hard capsule, was bioequivalent (similar pharmacokinetics) when compared to the coadministration of the components and may be considered as a suitable and simplified medication for cardiovascular disease management. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Safety of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Safety of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Preparation and in vivo evaluation of candesartan cilexetil solid dispersions was written by Kumar, Uppuluru Ashok;Suresh, Gande. And the article was included in Asian Journal of Pharmaceutical and Clinical Research in 2021.Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate This article mentions the following:

The present study aims at development of solid dispersions (SD) of candesartan cilexetil for enhanced solubility and bioavailability. About 18 SD formulations of candesartan cilexetil were prepared by solvent evaporation technique and evaluated. The in vitro release studies were conducted and the best formulation chosen was further characterized for Fourier transform IR spectroscopy, Scanning electron microscope, X-ray, and stability. The in vivo evaluation study conducted in rats. The formulation SD16 containing drug and Soluplus in 1:3 ratio along with 2% selective laser sintering was chosen optimal based on drug content (99.08%), and drug release (99.7%). In vivo studies conducted on SD16 showed that mean time to peak concentration (T_max) was 2.0±0.05 and 4±0.2 h for the optimized and pure drug, resp., while mean maximum drug concentration (C_max) was 570.63±2.65 ng/mL and was significant as compared to the candesartan pure drug 175.146±0.07 ng/mL. Area under curve AUC_0-∞ infinity for candesartan SD16 was higher (4860.61±1.05 ng.h/mL) than pure drug suspension 1480±1.72 ng.h/mL. Hence, the developed SD formulations enhanced the bioavailability of drug by 3 folds. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Name: 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Design, formulation, and characterization of stearic acid-based solid lipid nanoparticles of candesartan cilexetil to augment its oral bioavailability was written by Mahajan, Anu;Kaur, Satvinder. And the article was included in Asian Journal of Pharmaceutical and Clinical Research in 2018.Reference of 145040-37-5 This article mentions the following:

Objective: Poor aqueous solubility and suboptimal oral bioavailability hamper the therapeutic efficacy of candesartan cilexetil (CDC). This study is designed to prepare solid lipid nanoparticle (SLN) of CDC and to enhance the oral absorption of CDC compared with free drug suspension. The development and characterization of CDC-loaded SLN, using stearic acid as main encapsulating lipid, stabilized with poloxamer188 using “modified emulsification-ultrasonication technique.” Results: CDC-SLN with a total drug content of 88.33 ± 1.23% and entrapment efficiency of 78.28 ± 1.91%, with an average particle size of 197.9 nm and zeta potential value -21.3 mV, was prepared Differential scanning calorimetry and powder X-ray diffraction (PXRD) results confirmed the mol. encapsulation of the drug in amorphous state. CDC-SLN released 60.43% of drug in comparison to 17.11% released by CDC suspension in 24 h (p<0.05). The results of pharmacoKinetic studies in rat showed that AUC0-t of CDC-SLN was significantly enhanced over 3-folds than that of free drug suspension (p<0.05). Conclusion: SLN of CDC could be successful in improving the oral bioavailability of poorly soluble CDC. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Reference of 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Reference of 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Pharmacokinetics of liposomal curcumin (Lipocurc) infusion: effect of co-medication in cancer patients and comparison with healthy individuals was written by Bolger, Gordon T.;Licollari, Albert;Tan, Amin;Greil, Richard;Vcelar, Brigitta;Greil-Ressler, Sigrun;Weiss, Lukas;Schonlieb, Charlotte;Magnes, Teresa;Radl, Bianca;Majeed, Muhammed;Sordillo, Peter P.. And the article was included in Cancer Chemotherapy and Pharmacology in 2019.Related Products of 145040-37-5 This article mentions the following:

Purpose: Investigation of the impact of co-medication on the plasma levels of curcumin and tetrahydrocurcumin (THC) in cancer patients and a comparison of the pharmacokinetics of curcumin and plasma levels of THC between cancer patients and healthy individuals following i.v. infusion of Lipocurc (liposomal curcumin). Methods: Correlation anal. was used to determine the impact of co-medication on infusion rate normalized plasma levels of curcumin and THC in cancer patients and to compare the plasma levels of curcumin and THC at different infusion rates between cancer patients and healthy individuals. In vitro hepatocyte and red blood cell distribution experiments were conducted with Lipocurc to support clin. findings. Plasma concentration time data were analyzed by the non-compartmental method to determine and compare the pharmacokinetic parameters of curcumin in cancer patients and healthy individuals. Results: Of 44 co-medications studied, three medications targeting the renin-angiotensin system, Lisinopril, Ramipril, and Valsartan elevated plasma levels of curcumin and THC in three cancer patients infused with Lipocurc. Cell distribution experiments indicated that the disposition of curcumin in red blood cells may be a target for elevation of the plasma levels of curcumin. Plasma levels of curcumin in cancer patients increased to a greater extent with increased infusion rate compared to healthy individuals. Upon termination of infusion, the elimination phase for curcumin was shorter with a shorter terminal half-life and smaller volume of distribution for curcumin in cancer patients compared to healthy individuals. Conclusion: Either co-medications or health status, or both, can impact the pharmacokinetics of curcumin infusion (as Lipocurc) in cancer patients. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Related Products of 145040-37-5).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Related Products of 145040-37-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Enhancing onset of action of candesartan cilexetil by the preparation of fast dissolving film containing loaded Candesartan cilexetil nanoemulsion was written by Sahil;Malviya, Sarvesh Jain;Khune, Kalyani;Jain, Puspendra Kumar. And the article was included in World Journal of Pharmaceutical Research in 2019.COA of Formula: C33H34N6O6 This article mentions the following:

Candesartan cilexetil has limitation both in less bioavailability and onset of action. Therefor formulation to optimized the use of candesartan cilexetil. The purpose of this study was to develop nanoemulsion by using an appropriate oils, surfactant and co surfactant. Nanoemulsion was prepared by the spontaneous mixture of labrafil 2125, kolliphor RH 40 and PEG 400 with the ratio (0.5:9:5). The nanoemulsions were prepared by aqeous titration method. The solubility of drug was checked in different solvents, surfactant, oils and co surfactant in regulate to select the best solubilizing componenets for the preparation of nanoemulsion and then pseudoternary phase diagram was used as a useful device to evaluate the nanoemulsion area. The film was prepared by using a polymers (HPMC 5, HPMC 6, HPMC 15, and HPMC 50) and plasticizers. The method used for the preparation of film was petri plate method. It is an easy and low cost price method. The main purpose behind for the preparation of film was enhanced the onset of action and reduce the side effect. The evaluation of film was Invitro dissolution release, weight variation, folding endurance, film thickness, disintegration time, drug content release determination by used a zero order, first order, higuchi, koshmeyer plot graphs. The serious feature was type and ratio of oils, surfactant, co surfactant, and polymer and plasticizer concenteration influenced the film characters. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5COA of Formula: C33H34N6O6).

1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.COA of Formula: C33H34N6O6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem